| 000 | 05634cam a2200445Ii 4500 | ||
|---|---|---|---|
| 001 | 95462 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102112705.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 170228t20172017sz a ob 000 0 eng d | ||
| 020 |
_a3319501682 _q(electronic bk.) |
||
| 020 |
_a9783319501680 _q(electronic bk.) |
||
| 020 | _z3319501666 | ||
| 020 | _z9783319501666 | ||
| 040 |
_aN$T _cN$T _dN$T _dYDX _dGW5XE _dNJR _dIDEBK _dEBLCP _dOCLCF _dCOO _dIOG _dAZU _dVT2 _dUPM _dMERER _dESU _dZ5A _dOCLCQ _dJBG _dIAD _dICW _dICN _dOTZ _dOCLCQ _dU3W _dES-MaUEC _bspa |
||
| 050 | 4 |
_aRC845 _b2017 EB |
|
| 245 | 0 | 0 |
_aBiliary disease : _bfrom science to clinic _cGideon Hirschfield, David Adams, Evaggelia Liaskou, editors. |
| 264 | 1 |
_aCham, Switzerland _bSpringer International Publishing _c2017 |
|
| 264 | 4 | _c2017 | |
| 300 |
_a1 recurso en línea _bilustraciones (algunas a color) |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 504 | _aIncluye referencias bibliográficas | ||
| 505 | 0 | _aPreface; Contents; 1: The Clinical Burden of€Biliary Disease: A€Global Perspective; 1.1 Pediatric Cholestatic Disorders; 1.2 Extrahepatic Biliary Atresia; 1.3 Progressive Familial Intrahepatic Cholestatic Syndromes; 1.4 Drug-Induced Cholestasis; 1.5 Primary Biliary Cholangitis; 1.6 Primary Sclerosing Cholangitis; 1.7 Autoimmune Sclerosing Cholangitis/IgG4 Cholangiopathy; 1.8 Cholangiocarcinoma; 1.9 Gallbladder Cancer; 1.10 Gallstone Disease; References; 2: The Healthy Biliary Tree: Cellular and€Immune Biology; 2.1 The Normal Biliary Tree; 2.2 Development of€the€Bile Duct Epithelium. | |
| 505 | 8 | _a2.2.1 Morphogens and€Transcription Factors Involved in€Biliary Lineage Specification and€Bile Duct Formation2.3 Biological Properties Enabling Cholangiocytes to€Respond to€Liver Damage; 2.3.1 Reactive Ductular Cells: The€Main Element of€the€Hepatic Response to€Damage; 2.3.2 Cholangiocyte Proliferation; 2.3.3 Cholangiocyte Role in€Bile Secretion; 2.3.4 Cholangiocytes in€Inflammation; 2.3.5 Cholangiocytes and€Innate Immunity; 2.3.5.1 TLR Signaling; 2.3.5.2 Cholangiocyte Secretion of€IgA and€Antimicrobial Peptides; 2.3.6 Cholangiocyte Involvement in€Antigen Presentation; References. | |
| 505 | 8 | _a3.2.3 Vascular Diseases Associated with€Bile Duct Injury3.2.3.1 Hepatic Arterial Occlusion ("Ischaemic Cholangiopathy"); 3.2.3.2 "Sclerosing Cholangitis in€Critically Ill Patients" (SC-CIP); 3.2.3.3 Portal Vein Occlusion ("Portal Hypertensive Biliopathy"); 3.2.4 Infective Causes of€Biliary Disease; 3.2.5 Drugs and€Iatrogenic Causes of€Biliary Disease; 3.2.5.1 Drug-Induced Cholestasis; 3.2.5.2 Intestinal Failure-Associated Liver Disease (IFALD); 3.2.6 Neoplastic Diseases Associated with€Cholestasis or Bile Duct Injury; 3.2.6.1 Langerhans Cell Histiocytosis. | |
| 505 | 8 | _a3: Pathological Features of€Biliary Disease in€Children and€Adults3.1 What Are the€Pathological Features of€Biliary Disease?; 3.1.1 Bile Duct Lesions; 3.1.2 Ductular Reaction; 3.1.3 Cholestasis; 3.1.3.1 Bilirubinostasis; 3.1.3.2 Cholate Stasis; 3.1.4 Inflammation; 3.1.5 Fibrosis; 3.1.6 Assessment of€Disease Severity in€Chronic Biliary Disease: Grading and€Staging; 3.2 Histological Changes in€Specific Diseases; 3.2.1 Developmental/Genetic Diseases; 3.2.1.1 Biliary Atresia; 3.2.1.2 Syndromic and€Non-syndromic Paucity of€Intrahepatic Bile Ducts. | |
| 505 | 8 | _aSyndromic Paucity of€Intrahepatic Bile Ducts (Alagille Syndrome)Non-syndromic Paucity of€Intrahepatic Bile Ducts; 3.2.1.3 Diseases Associated with€Ductal Plate Malformation; 3.2.1.4 Cystic Fibrosis; 3.2.1.5 Progressive Familial Intrahepatic Cholestasis (PFIC); 3.2.2 Immune-Mediated Biliary Diseases; 3.2.2.1 Primary Biliary Cholangitis (PBC); 3.2.2.2 Primary Sclerosing Cholangitis (PSC); 3.2.2.3 Autoimmune Sclerosing Cholangitis (ASC); 3.2.2.4 IgG4-Associated Sclerosing Cholangitis; 3.2.2.5 Sarcoidosis; 3.2.2.6 Transplant-Related Bile Duct Diseases. | |
| 520 | 3 | _aThis book addresses the current understanding of the diagnosis and management of biliary disease across all ages, with emphasis on how the latest advances in clinical science may be integrated into current and future therapies. The coverage is wide ranging, encompassing congenital and acquired conditions including cholestatic syndromes, biliary atresia, drug-induced cholestasis, primary biliary cholangitis/cirrhosis, primary sclerosing cholangitis, cholangiocarcinoma, gallstone disease, and autoimmune sclerosing cholangitis. With contributions from basic and clinical scientists, the relevance of state-of-the-art mechanistic biology to diagnosis, treatment, and future opportunities for drug design is clearly explained. The balance between science and clinical practice will ensure that this book makes a lasting contribution to the field. A broad readership will find the book easy to access and a rich source of information on current best practice and evolving management strategies. | |
| 650 | 7 |
_aVías biliares _xEnfermedades _2embne _0(OCoLC)fst00831716 _0 _9677697 |
|
| 700 | 1 |
_aAdams, David, _d1958- _eeditor literario |
|
| 700 | 1 |
_aHirschfield, Gideon M., _eeditor literario |
|
| 700 | 1 |
_aLiaskou, Evaggelia, _eeditor literario |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-50168-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 988 | _aSpringer_Medicine_2017 | ||
| 998 |
_b02/2018 _dz _e- _zSI |
||
| 999 |
_c95462 _d95462 _x1 |
||